Literature DB >> 32851558

Comparison of vessel density in macular and peripapillary regions between primary open-angle glaucoma and pseudoexfoliation glaucoma using OCTA.

Sevgi Subasi1, Nursen Yuksel2, Ece Basaran2, Dilara Pirhan2.   

Abstract

PURPOSE: The aim of our study was to compare macular and peripapillary vessel density using optical coherence tomography angiography (OCTA) between eyes with primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PXG).
METHODS: Thirty-six POAG and 34 PXG eyes with similar visual field defect (no statistically significant difference between average mean deviation and pattern standard deviation scores) were included. Macular superficial vessel density (msVD) in the superficial macular layer and foveal avascular zone (FAZ) parameters were assessed with (6 × 6 mm) and peripapillary vessel density (ppVD) in the radial peripapillary capillary (RPC) with (4.5 × 4.5 mm) OCTA scans. Area under the receiver operating curve was used for assessing diagnostic capability.
RESULTS: In PXG group, all msVD parameters had lesser values, and especially in parafoveal region, statistically significant decrease was shown (p = 0.008) in all subdivisions except nasal (p = 0.053). FAZ area was more larger in PXG [0.32(0.25-0.36)] than POAG [0.28(0.22-0.39)],(p = 0.944). FAZ density - 300 μm had statistically significant decrease in PXG (47.22 ± 6.92) according to POAG groups (50.63 ± 7.25) (p = 0.048). Most of RPC VD parameters had decreasing values in PXG group (p > 0.05). VDs and corresponding thicknesses had significant remarkable positive correlation in both macular and peripapillary regions. Significant remarkable negative correlations were observed between fovea VD and FAZ area, FAZ perimeter and between fovea thickness and FAZ area, FAZ perimeter.
CONCLUSION: PXG eyes were found to have lesser values in terms of VD in the macular area, especially in the parafoveal and FD-300 regions, compared to POAG eyes which had similar functional and structural glaucomatous damage. Patients whose etiology was PXG and who seemed to have the same functional damage as those with POAG were actually found to have greater macular vascular damage. In addition, it was observed that macular vascular parameters correlated with peripapillary vascular parameters.

Entities:  

Keywords:  Optical coherence tomography angiography; Primary open-angle glaucoma; Pseudoexfoliation glaucoma; Visual field defect

Mesh:

Year:  2020        PMID: 32851558     DOI: 10.1007/s10792-020-01564-5

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  1 in total

1.  Impact of Pupil Dilation on Optical Coherence Tomography Angiography Retinal Microvasculature in Healthy Eyes.

Authors:  George Villatoro; Christopher Bowd; James A Proudfoot; Patricia I C Manalastas; Khoa D Nguyen; Huiyuan Hou; Rafaella C Penteado; Andrew J Li; Sasan Moghimi; Elham Ghahari; Robert N Weinreb; Linda M Zangwill
Journal:  J Glaucoma       Date:  2020-11       Impact factor: 2.503

  1 in total
  3 in total

1.  Optic nerve head microvascular characteristics in patients with unilateral pseudoexfoliation syndrome: an optical coherence tomography angiography study.

Authors:  Ozlem Dikmetas; Sepideh Lotfi Sadigh; Cansev Şekerler; Sibel Kocabeyoğlu; Sevilay Karahan; Ali Bulent Cankaya
Journal:  Int Ophthalmol       Date:  2022-01-30       Impact factor: 2.029

Review 2.  The Role of Vessel Density as Measured by Optical Coherence Tomography Angiography in the Evaluation of Pseudoexfoliative Glaucoma: A Review of the Literature.

Authors:  Irini Chatziralli; Ilias Milionis; Aikaterini Christodoulou; Panagiotis Theodossiadis; George Kitsos
Journal:  Ophthalmol Ther       Date:  2022-02-24

3.  Evaluation of macular microvascular density using optical coherence tomography angiography in patients with Posner-Schlossman syndrome.

Authors:  Xiu-Juan Guo; Di Chen; Li-Jun Zhou; Shu-Ke Luo; Yan Lu; Jing-Jing Guo
Journal:  BMC Ophthalmol       Date:  2022-08-10       Impact factor: 2.086

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.